Palvella Therapeutics (PVLA) Other Accumulated Expenses (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Other Accumulated Expenses of $960000.0 for Q1 2026, up 29.38% year-over-year from $742000.0 in Q1 2025, and up 36.17% quarter-over-quarter from $705000.0 in Q4 2025.
Palvella Therapeutics (PVLA) Other Accumulated Expenses (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Other Accumulated Expenses for 14 consecutive years, with $960000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 29.38% year-over-year to $960000.0; the TTM figure through Mar 2026 stood at $960000.0 (up 29.38% YoY), while the FY2025 annual figure was $705000.0, down 40.71% from the prior year.
- Other Accumulated Expenses improved to $960000.0 in Q1 2026 per PVLA's latest filing, from $705000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $1.2 million in Q4 2024 and bottomed at $120000.0 in Q4 2023.
- Historically, Other Accumulated Expenses has averaged $711176.5 across 5 years, with a median of $637000.0 in 2022.
- Annual changes were most pronounced in 2023 — Other Accumulated Expenses plunged 75.16% — and 2024, when it surged 890.83%.
- Palvella Therapeutics' Other Accumulated Expenses stood at $483000.0 in 2022, then slumped by 75.16% to $120000.0 in 2023, then soared by 890.83% to $1.2 million in 2024, then slumped by 40.71% to $705000.0 in 2025, then jumped by 36.17% to $960000.0 in 2026.
- Business Quant data shows PVLA's Other Accumulated Expenses at $960000.0 in Q1 2026, $705000.0 in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.64 Mn |
| Mar 31, 2026 | 960,000.00 |
| Dec 31, 2025 | 705,000.00 |
| Sep 30, 2025 | 1.05 Mn |
| Jun 30, 2025 | 971,000.00 |
| Mar 31, 2025 | 742,000.00 |
| Dec 31, 2024 | 1.19 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 1.01 Mn |
| Mar 31, 2024 | 335,000.00 |
| Dec 31, 2023 | 120,000.00 |
| Sep 30, 2023 | 575,000.00 |
| Jun 30, 2023 | 497,000.00 |
| Mar 31, 2023 | 590,000.00 |
| Dec 31, 2022 | 483,000.00 |
| Sep 30, 2022 | 581,000.00 |
| Jun 30, 2022 | 610,000.00 |
| Mar 31, 2022 | 637,000.00 |
| Dec 31, 2021 | 393,000.00 |
| Sep 30, 2021 | 222,000.00 |